Pharmaceutical, Foods & Drugs

About Pharmaceutical, Foods & Drugs Industry

The pharmaceutical industry in India ranks 3rd in the world terms of volume and 14th in terms of value. According to Department of Pharmaceuticals, Ministry of Chemicals, and Fertilizers, the total turnover of India's pharmaceuticals industry between 2008 and September 2009 was US$21.04 billion. Hyderabad, Mumbai, Bangalore, and Ahmedabad are the major pharmaceutical hubs of India. The domestic market was worth US$13.8 billion in 2013. For drug industry is a very positive mark however there are certain challenges for pharmaceutical players in the country and these challenges are: Good manufacturing practices (GMP) and Compliance: Issues in some manner these are always been a problem for the drug companies. The current going bruit that the USFDA (United States Food and Drug Administration is trying to block the growth of the Indian drug firms. Why Indian firms having dependency of USFDA? USFDA approval is vital as the largest medicine users in the United States of America and at the same time India is a major exporter to them. The view of the USFDA is carefully weighed to be the standard in the biopharma field as well. The Indian drug companies putting efforts to ameliorate their standards and GMP, compliance challenges could be sorted by having functionaries who are more rigorous or strict and inspections on a regular manner can be planned and executed fragmented sector. India is the source of 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs). The export of generic drugs is one of India's core strengths. The export of pharma stood at USD 16.3 bn in 2015-16. Pharma exports recorded CAGR of 11.9% for decade ending 2015-16. Third largest pharmaceuticals market by 2020 in terms of incremental growth 100% Foreign Direct Investment (FDI) is allowed under the automatic route for green field pharma and 74% FDI in brownfield pharma under automatic route, beyond 74% FDI is through government approval route

Policy Regime

Pharma sector exports recorded CAGR of 11.9% for decade ending 2015-16. Third largest pharmaceuticals market by 2020 in terms of incremental growth 100% Foreign Direct Investment (FDI) is allowed under the automatic route for green field pharma and 74% FDI in brownfield pharma under automatic route, beyond 74% FDI is through government approval route.

Major players of the Industries

Indian companies are also starting to adapt their product development processes to the new environment. For years, firms have made their ways into the global market by researching generic competitors to patented drugs and following up with litigation to challenge the patent. This approach remains untouched by the new patent regime and looks to increase in the future. The top 9 companies of Indian market is given below

• ●Sun Pharmaceutical
• ●Lupin Ltd
• ●Dr. Reddy's Laboratories
• ●Cipla
• ●Aurobindo Pharma
• ●Zydus Cadila Healthcare
• ●Piramal Enterprises
• ●Glenmark Pharmaceuticals
• ●Torrent Pharmaceuticals

Legal services of Preach Law LLP

The firm provides advice on cutting-edge issues that cover multiple legal and business disciplines. Our expertise and understanding of the business is the foundation for providing full range of legal services including

• ●Arbitrations & Litigation
• ●Foreign Investments
• ●Regulatory
• ●Structuring
• ●Offset policy
• ●Statutory Compliances
• ●Joint Ventures
• ●Contracts
• ●Teaming Agreements
• ●Auction/Bid Management etc
• ●Tax & Regulatory Structuring
• ●Sourcing/Supply and Service Agreements
• ●Regulatory Approvals/Representations
• ●Advisory Services
• ●Information Technology Enablement
• ●Review/Appeal of Administration Decisions
• ●Trademark, Patents and Copyrights registration, and prosecution.